Kailera Therapeutics, Inc. KLRA
—
11.22
(0.76)
(6.34%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow KLRA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (39.14%) | 0.00% | — | — | ||
ROIC |
(79.67%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(27.98%) | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(2.86) | (10,784.81) | 0.00 | 0.00 | |
Free Cash Flow |
(292.28) | (232.95) | (164.64) | — | |
Piotroski F-Score |
0.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(14.36%) | (21.58%) | (13.93%) | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
1.23 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.33 | 0.29 | 0.22 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(2.86) | (10,784.81) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates